摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(3R,5S)-(-)-(3,5-trans)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-neopentyl-2-oxo-4,1-benzoxazepine-3-acetic acid | 171868-39-6

中文名称
——
中文别名
——
英文名称
(3R,5S)-(-)-(3,5-trans)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-neopentyl-2-oxo-4,1-benzoxazepine-3-acetic acid
英文别名
[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl]acetic acid;(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-neopentyl-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepine-3-acetic acid;2-[(3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-(2,2-dimethylpropyl)-2-oxo-5H-4,1-benzoxazepin-3-yl]acetic acid
(3R,5S)-(-)-(3,5-trans)-7-chloro-5-(2,3-dimethoxyphenyl)-1,2,3,5-tetrahydro-1-neopentyl-2-oxo-4,1-benzoxazepine-3-acetic acid化学式
CAS
171868-39-6
化学式
C24H28ClNO6
mdl
——
分子量
461.942
InChiKey
KNWJPGLBKMPTEW-TZIWHRDSSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    644.3±55.0 °C(Predicted)
  • 密度:
    1.228±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    4.3
  • 重原子数:
    32
  • 可旋转键数:
    7
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.42
  • 拓扑面积:
    85.3
  • 氢给体数:
    1
  • 氢受体数:
    6

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Benzoxazepinones and their use as squalene synthase inhibitors
    申请人:——
    公开号:US20030078251A1
    公开(公告)日:2003-04-24
    There is disclosed a compound represented by the formula [I]: 1 wherein R 1 is optionally substituted 1-carboxyethyl group, optionally substituted alkyl-sulfonyl group, optionally substituted (carboxy-cycloalkyl)-alkyl group, —X 1 —X 2 —Ar—X 3 —X 4 —COOH (wherein X 1 and X 4 are a bond or alkylene group, X 2 and X 3 are a bond, —O—, —S—, Ar is divalent aromatic group etc.), R 2 is alkyl group optionally substituted with alkanoyloxy group and/or hydroxy group, R 3 is alkyl group, and W is halogen atom, etc., or a salt thereof. The compound has the cholesterol lowering activity and the triglyceride lowering activity and is useful for preventing and/or treating hyperlipidemia.
    披露了一种由公式[I]表示的化合物: 1 其中R 1 是可选地取代的1-羧乙基,可选地取代的烷基亚磺酰基,可选地取代的(羧基环烷基)-烷基,—X 1 —X 2 —Ar—X 3 —X 4 —COOH(其中X 1 和X 4 是键或亚烷基,X 2 和X 3 是键,—O—,—S—,Ar是二价芳香族等),R 2 是可选地由酰氧基和/或羟基取代的烷基,R 3 是烷基,W是卤素原子等,或其盐。该化合物具有降低胆固醇活性和降低甘油三酯活性,用于预防或治疗高脂血症。
  • Novel 4,1-benzoxazepine derivatives with potent squalene synthase inhibitory activities
    作者:Takashi Miki、Masakuni Kori、Hiroshi Mabuchi、Hiroshi Banno、Ryu-ichi Tozawa、Masahira Nakamura、Shigekazu Itokawa、Yasuo Sugiyama、Hidefumi Yukimasa
    DOI:10.1016/s0968-0896(01)00290-5
    日期:2002.2
    inhibitory activity. Among such compounds, the 5-(2,3-dimethoxyphenyl) derivative 2t exhibited potent inhibition of cholesterol biosynthesis in HepG2 cells. As a result of optical resolution study of 2t, the absolute stereochemistry required for inhibitory activity was determined to be 3R,5S. In vivo study showed that the sodium salt of (3R,5S)-7-chloro-5-(2,3-dimethoxyphenyl)-1-neopentyl-2-oxo-1,2,3,5-tetrahydro-4
    合成了一系列的(3,5-反式)-2-氧代-5-苯基-1,2,3,5-四氢-4,1-苯并x氮平衍生物,并评价了其对角鲨烯合酶的抑制作用和对胆固醇生物合成的抑制作用。通过修饰先导化合物1a和1b的取代基,发现在1位带有异丁基和新戊基,在7位具有氯原子和在氯原子上具有4,1-苯并氮杂氮杂-3-乙酸衍生物。在5-苯环的2'-位上的甲氧基具有强力的角鲨烯合酶抑制活性。在这些化合物中,5-(2,3-二甲氧基苯基)衍生物2t在HepG2细胞中显示出有效的胆固醇生物合成抑制作用。作为2t光学拆分研究的结果,抑制活性所需的绝对立体化学被确定为3R,5S。
  • Benzoxazepine and benzothiazepine derivatives useful as antihypertriglyceridemic agents
    申请人:TAKEDA CHEMICAL INDUSTRIES, LTD.
    公开号:EP0705607A2
    公开(公告)日:1996-04-10
    An antihypertriglyceridemic composition comprising a compound of formula (I) wherein R1 represents a hydrogen atom or a hydrocarbon group that may be substituted; R2 and R3 may be the same or different and each represents a hydrogen atom, a hydrocarbon group that may be substituted, or a heterocyclic group that may be substituted; X' represents a substituent comprising a carboxyl group that may be esterified, a carbamoyl group that may be substituted, a hydroxyl group that may be substituted, an amino group that may be substituted, or an optionally substituted heterocyclic group having a hydrogen atom that may be deprotonated; ring A represents a benzene ring that may be substituted or a heterocyclic ring that may be substituted; ring J' represents a 7- or 8-membered heterocyclic ring having at most 3 hetero-atoms as ring constituent members; and ring J' may have a further substituent in addition to R1, R2, R3 and X', or a pharmacologically acceptable salt thereof. The composition has a plasma triglyceride concentration-lowering activity, and therefore is useful for the prophylaxis or treatment of hyperlipemia, such as hypertriglyceridemia.
    一种抗高三酸甘油酯组合物,包括化合物(I)的结构式,其中R1代表氢原子或可被取代的碳氢基团;R2和R3可以相同或不同,每个代表氢原子,可被取代的碳氢基团,或可被取代的杂环基团;X'代表取代基,包括可酯化的羧基,可被取代的氨基甲酰基,可被取代的羟基,可被取代的氨基,或者是具有可去质子的氢原子的可选取代杂环基团;环A代表可以被取代的苯环或者可以被取代的杂环;环J'代表最多有3个杂原子作为环成员的7-或8-成员杂环,除了R1、R2、R3和X'之外,环J'还可以具有进一步的取代基,或其药学上可接受的盐。该组合物具有降低血浆三酸甘油酯浓度的活性,因此对于预防或治疗高脂血症,如高三酸甘油酯血症,有用。
  • Benzoxazepine compounds, their production and use
    申请人:Takeda Chemical Industries, Ltd.
    公开号:US20040072819A1
    公开(公告)日:2004-04-15
    This invention provides new benzoxazepine compounds represented by the formula: 1 [wherein R stands for a lower alkyl group optionally substituted with a hydroxyl group, X stands for an optionally substituted carbamoyl group or an optionally substituted heterocyclic group having a deprotonatable hydrogen atom, R 1 stands for a lower alkyl group and W stands for a halogen atom] having activities of lowering chlesterol-level and lowering trigluceride-level, and being useful for prophylaxis and therapy of hyperlipidemia.
    这项发明提供了由下式表示的新苯并噁唑化合物:1 [其中R代表可选择带有羟基的低碳基,X代表可选择取代的氨基甲酰基或可去质子的氮杂环基,R1代表低碳基,W代表卤素原子],具有降低胆固醇水平和降低三酰甘油水平的活性,并且对于预防和治疗高脂血症是有用的。
  • Preventives/remedies for organ functional disorders and organ dysfunction
    申请人:——
    公开号:US20040204500A1
    公开(公告)日:2004-10-14
    The present invention provides an agent for preventing or treating organ functional disorders, an agent for preventing or treating organ dysfunction and an agent for preventing or treating obesity and deuteropathy thereof, each of which comprises a compound having an effect of increasing ubiquinone or a salt thereof or a prodrug thereof; as well as a ubiquinone increasing agent comprising a compound having a squalene synthase inhibitory effect or a salt thereof or a prodrug thereof.
    本发明提供了一种用于预防或治疗器官功能障碍的药剂、用于预防或治疗器官功能障碍的药剂以及用于预防或治疗肥胖和其中的脱水症的药剂,每种药剂均包含具有增加泛醌或其盐或其前药的效果的化合物;以及一种增加泛醌的剂量,包括具有角鲨烷合成酶抑制作用或其盐或前药的化合物。
查看更多